Abstract
Introduction
Molecular targeted cancer therapies are the biggest and fastest growing class
of cancer drugs in terms of sales. As growth of revenues from cytotoxic
therapies and antihormonal therapies has slowed and many key brands in these
classes face imminent patent expiries, it is unsurprising that the major
oncology companies have shifted their focus towards the molecular targeted
cancer therapies market.
Key reasons to purchase this research
- Quantify the performance of each of the marketed molecular targeted cancer
therapies in the seven major markets over the period 2008 to 2018
- Assess the changing key opportunities and threats both for currently
marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success
| 
View Cart
